Combined Diffuse Astrocytoma and Pleomorphic Xanthoastrocytoma Grade III Sharing IDH1 R132H Mutation

被引:1
|
作者
Tourne, Morgan [1 ]
Tauziede-Espariat, Arnault [1 ]
Dezamis, Edouard [2 ]
Saffroy, Raphael [3 ]
Dhermain, Frederic [4 ]
Chretien, Fabrice [1 ]
Varlet, Pascale [1 ]
机构
[1] Descartes Univ, St Anne Hosp, Dept Neuropathol, Paris, France
[2] Descartes Univ, St Anne Hosp, Dept Neurosurg, Paris, France
[3] Hop Univ Paris Sud, Hop Paul Brousse, AP HP, Dept Biochem & Oncogenet, Villejuif, France
[4] Gustave Roussy Canc Campus, Dept Radiat Oncol, Villejuif, France
关键词
Anaplastic astrocytoma; BRAF V600E; Collision tumour; IDH1; mutation; Pleomorphic xanthoastrocytoma; COLLISION TUMOR; MENINGIOMA; DIFFERENTIATION; FEATURES; GLIOMAS; BRAIN;
D O I
10.1016/j.wneu.2018.05.156
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUND: Collision tumors are often difficult to distinguish from intratumoral heterogeneity in diffuse gliomas. CASE DESCRIPTION: We report the case of a 44-year-old woman admitted for intracranial hypertension. Magnetic resonance imaging revealed a right intra-axial frontal mass, composed of a hypervascular nodular portion contrasting with a large nonenhanced infiltrative and muliticystic portion. Histopathologic examination showed the occurrence of two morphologically different gliomas. The largest component corresponded to an anaplastic astrocytoma, IDH1-mutated. The second corresponded to a leptomeningeal nodule, reminiscent of a pleomorphic xanthoastrocytoma. Both tumoral components exhibited anaplastic features, World Health Organization grade III. Immunohistochemical and molecular studies showed that the 2 components were identical, IDH1 R132H mutated but without BRAF V600E mutation. Tumor progression was assessed 2 years after surgery, after radiotherapy and chemotherapy, showing supratentorial leptomeningeal dissemination. CONCLUSIONS: Collision tumors and combined neoplasms have been rarely described in the brain and only 4 similar articles report the synchronous occurrence of 2 primary gliomas. A review of the literature is proposed, focusing on criteria that could be used to discriminate them.
引用
收藏
页码:316 / 321
页数:6
相关论文
共 50 条
  • [41] Oncogenic MicroRNA-20a is downregulated by the HIF-1α/c-MYC pathway in IDH1 R132H-mutant glioma
    Xu, Qingfu
    Ahmed, A. Karim
    Zhu, Yan
    Wang, Kimberly
    Lv, Shengqing
    Li, Yunqing
    Jiang, Yugang
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 499 (04) : 882 - 888
  • [42] Immunohistochemically detected IDH1R132H mutation is rare and mostly heterogeneous in prostate cancer
    Hinsch, Andrea
    Brolund, Meta
    Hube-Magg, Claudia
    Kluth, Martina
    Simon, Ronald
    Moeller-Koop, Christina
    Sauter, Guido
    Steurer, Stefan
    Luebke, Andreas
    Angerer, Alexander
    Wittmer, Corinna
    Neubauer, Emily
    Goebel, Cosima
    Buescheck, Franziska
    Minner, Sarah
    Wilczak, Waldemar
    Schlomm, Thorsten
    Jacobsen, Frank
    Clauditz, Till Sebastian
    Krech, Till
    Tsourlakis, Maria Christina
    Schroeder, Cornelia
    WORLD JOURNAL OF UROLOGY, 2018, 36 (06) : 877 - 882
  • [43] Targeting the IDH1R132H mutation in gliomas by CRISPR/Cas precision base editing
    Weber, Remi
    Vasella, Flavio
    Klimko, Artsiom
    Silginer, Manuela
    Lamfers, Martine
    Neidert, Marian Christoph
    Regli, Luca
    Schwank, Gerald
    Weller, Michael
    NEURO-ONCOLOGY ADVANCES, 2024, 6 (01)
  • [44] Machine learning-based quantitative texture analysis of conventional MRI combined with ADC maps for assessment of IDH1 mutation in high-grade gliomas
    Alis, Deniz
    Bagcilar, Omer
    Senli, Yeseren Deniz
    Yergin, Mert
    Isler, Cihan
    Kocer, Naci
    Islak, Civan
    Kizilkilic, Osman
    JAPANESE JOURNAL OF RADIOLOGY, 2020, 38 (02) : 135 - 143
  • [45] Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation
    Sahm, Felix
    Capper, David
    Meyer, Jochen
    Hartmann, Christian
    Herpel, Esther
    Andrulis, Mindaugas
    Mechtersheimer, Gunhild
    Petersen, Iver
    Paulus, Werner
    von Deimling, Andreas
    HISTOPATHOLOGY, 2011, 58 (07) : 1167 - 1172
  • [46] Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma
    Tanaka, Kazuhiro
    Sasayama, Takashi
    Mizukawa, Katsu
    Takata, Kumi
    Sulaiman, Nor Shazrina
    Nishihara, Masamitsu
    Kohta, Masaaki
    Sasaki, Ryohei
    Hirose, Takanori
    Itoh, Tomoo
    Kohmura, Eiji
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2015, 138 : 37 - 44
  • [47] A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas
    Fujii, Yuki
    Ogasawara, Satoshi
    Oki, Hiroharu
    Liu, Xing
    Kaneko, Mika K.
    Takano, Shingo
    Kato, Yukinari
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2015, 466 (04) : 733 - 739
  • [48] Non-canonical IDH Mutation Frequency in IDH1-R132H-Negative Glioblastoma Patients Older Than 54 Years
    Pryzbylski, Amber L.
    Kollmeyer, Thomas M.
    Praska, Corinne E.
    Raghunathan, Aditya
    Jentoft, Mark E.
    Giannini, Caterina
    Vaubel, Rachael A.
    Halling, Kevin C.
    Zheng, Gang
    DiGuardo, Margaret A.
    Kipp, Benjamin R.
    Jenkins, Robert B.
    Ida, Cristiane M.
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2021, 80 (08) : 804 - 806
  • [49] A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation
    Kato, Yukinari
    Jin, Genglin
    Kuan, Chien-Tsun
    McLendon, Roger E.
    Yan, Hai
    Bigner, Darell D.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 390 (03) : 547 - 551
  • [50] Machine learning-based quantitative texture analysis of conventional MRI combined with ADC maps for assessment of IDH1 mutation in high-grade gliomas
    Deniz Alis
    Omer Bagcilar
    Yeseren Deniz Senli
    Mert Yergin
    Cihan Isler
    Naci Kocer
    Civan Islak
    Osman Kizilkilic
    Japanese Journal of Radiology, 2020, 38 : 135 - 143